Correlates of glucagon-like peptide-1 receptor agonist use among patients with atherosclerotic cardiovascular disease and type 2 diabetes mellitus (from the department of veterans affairs)
Document Type
Article
Department
Office of the Provost; Cardiology
Abstract
This study used data from the Veterans Affairs administrative and clinical dataset to evaluate determinants of glucagon-like peptide-1 receptor agonist (GLP-1 RA) use among patients with concomitant atherosclerotic cardiovascular disease and diabetes mellitus and an antecedent primary care provider visit. The prevalence of GLP-1 RA use was 8.0%. In multivariable-adjusted models, White race, hypertension, obesity, higher hemoglobin A1c, ischemic heart disease, chronic kidney disease, a higher number of primary care provider visits, and previous cardiology or endocrinology visits were directly associated with GLP-1 RA use. Older age, having a physician primary care provider, and receiving care at a teaching facility were inversely associated with GLP-1 RA use. Our data can help inform targeted interventions to promote equitable access to GLP-1 RA and incentivize the adoption of these disease-modifying agents in high-risk patient populations.
Publication (Name of Journal)
The American journal of cardiology
Recommended Citation
Rifai, M. A.,
Vaughan, E. M.,
Abushamat, L. A.,
Lee, M.,
Ramsey, D. J.,
Gupta, K.,
Navaneethan, S. D.,
Virani, S. S.
(2022). Correlates of glucagon-like peptide-1 receptor agonist use among patients with atherosclerotic cardiovascular disease and type 2 diabetes mellitus (from the department of veterans affairs). The American journal of cardiology, 172, 7-10.
Available at:
https://ecommons.aku.edu/provost_office/161
Comments
Issue No are not provided by the author/publisher. This work was published before the author joined Aga Khan University.